Questcor hires new CFO

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Questcor hires new CFO

Questcor Pharmaceuticals ($QCOR) appointed Rajesh Asarpota as the company's new CFO and Michael Mulroy, the previous CFO, as executive vice president for strategic affairs and general counsel. Asarpota joins Questcor from Life Technologies, where he most recently served as vice president of finance. Release

Questcor
Rajesh Asarpota has become the new CFO.


Cleave Biosciences
Dr. Alessandra Cesano is the new chief medical officer.


Biotech

> Dr. Alessandra Cesano has joined Cleave Biosciences as chief medical officer. Release

> Patrick O'Connor has resigned as chief scientific officer and senior vice president, head of research of Ignyta. Release

> Techne ($TECH) has appointed James Hippel as CFO. Release

> Pathway Genomics has appointed Ardy Arianpour as chief strategy officer. Release

> Heat Biologics ($HTBX) has appointed Robert Corder as vice president of manufacturing. Release

> Robin Jackman joined Leading BioSciences as the company's new CEO, succeeding Stephen Flaim, who will resume his post as chairman. Release

> Nymox Pharmaceutical ($NYMX) has appointed Andre Monette as chief financial officer. Release

> Australian biotech Novogen ($NVGN) appointed Justine Stehn and Peter Gunning--co-inventors of the company's anti-tropomyosin technology--to be director of the ATM program and scientific advisory panel member, respectively. Release

> Enanta Pharmaceuticals ($ENTA) has appointed Timothy Ocain as senior vice president, new product strategy and development. Release

> Tetraphase Pharmaceuticals ($TTPH) has appointed Craig Thompson as chief operating officer. Release

> Aaron Berg has been promoted to senior vice president of marketing and sales at Amarin ($AMRN). Release

> Pluristem Therapeutics ($PSTI) appointed Yaky Yanay as the company's president and COO and Boaz Gur-Lavie as its CFO and secretary. Release

> Aesica brought on Ian Muir to be the company's commercial managing director, a new position. Release

> Leading breast cancer expert Dr. George W. Sledge joined Syndax Pharmaceuticals as an independent director. Release

> Ignyta appointed Matthew Onaitis as general counsel and secretary. Release

Pharma

> Nicox S.A. ($NCOX) has appointed Evelyne Nguyen as chief financial officer. Release

> aTyr Pharma brought on Frederic Chereau as the company's president and COO. Release

> Rudolf Kwan and Wing-Kai Chan joined Kinex Pharmaceuticals as chief medical officer and head of clinical operations in the Asia/Pacific region, respectively. Release

Biotech IT

> Richard Keckhas been named president and CEO of PhDx Systems. Release

CRO

> Dave Peters has joined WCCT Global as chief financial officer. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.